Guggenheim Capital LLC Alnylam Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 15,248 shares of ALNY stock, worth $3.71 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

15,248

Previous 19,187 20.53%

Holding current value

$3.71 Million

Previous $4.66 Million 10.04%

% of portfolio

0.03%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$233.81 - $287.01 $920,977 - $1.13 Million	-3,939 Reduced 20.53%	15,248 $4.19 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $283,037 - $487,825	-1,975 Reduced 9.33%	19,187 $4.66 Million
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $499,745 - $676,060	3,411 Added 19.22%	21,162 $3.16 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $76,764 - $99,660	507 Added 2.94%	17,751 $3.4 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $413,604 - $512,616	-2,422 Reduced 12.32%	17,244 $3.05 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $59,203 - $67,856	-320 Reduced 1.6%	19,666 $3.74 Million
Q1 2023 May 10, 2023	SELL	$182.66 - $235.53 $151,790 - $195,725	-831 Reduced 3.99%	19,986 $4 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $289,426 - $376,443	1,560 Added 8.1%	20,817 $4.95 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $843,985 - $1.41 Million	-6,092 Reduced 24.03%	19,257 $3.85 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $47,565 - $66,869	-395 Reduced 1.53%	25,349 $3.7 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $71,347 - $97,563	-561 Reduced 2.13%	25,744 $4.2 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $392,677 - $515,062	2,461 Added 10.32%	26,305 $4.46 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $355,286 - $434,778	-2,093 Reduced 8.07%	23,844 $4.5 Million
Q2 2021 Aug 13, 2021	SELL	$128.63 - $176.89 $450,333 - $619,291	-3,501 Reduced 11.89%	25,937 $4.4 Million
Q1 2021 May 13, 2021	SELL	$126.83 - $175.69 $279,660 - $387,396	-2,205 Reduced 6.97%	29,438 $4.16 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $787,130 - $940,947	-6,401 Reduced 16.83%	31,643 $4.11 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $860,933 - $1.18 Million	-7,104 Reduced 15.73%	38,044 $5.54 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $347,019 - $520,945	3,330 Added 7.96%	45,148 $6.69 Million
Q1 2020 Jun 02, 2020	SELL	$93.12 - $133.99 $855,493 - $1.23 Million	-9,187 Reduced 18.01%	41,818 $4.55 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $23,470 - $39,132	315 Added 0.62%	51,005 $5.87 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $526,999 - $652,766	-7,433 Reduced 12.79%	50,690 $4.08 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $140,545 - $198,013	-2,134 Reduced 3.54%	58,123 $4.22 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $270,448 - $347,353	-3,717 Reduced 5.81%	60,257 $5.63 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $217,652 - $306,770	3,473 Added 5.74%	63,974 $4.66 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $409,593 - $574,095	4,680 Added 8.38%	60,501 $5.3 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $241,704 - $295,048	2,737 Added 5.16%	55,821 $5.5 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $69,552 - $89,124	600 Added 1.14%	53,084 $6.32 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $3.78 Million - $4.62 Million	-32,983 Reduced 38.59%	52,484 $6.67 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $6.2 Million - $10.1 Million	85,467	85,467 $10 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Alnylam Pharmaceuticals, Inc. Transaction History